Skip to main content
SpringerLink
Log in
Book cover

Tumor Microenvironment pp 47–58Cite as

IL-17 Signaling in the Tumor Microenvironment

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1240))

Abstract

Inflammation is recognized as representing a double-edged sword in terms of tumor growth, in some instances contributing to attenuation of growth and in others to enhanced progression and metastasis. Extracellular signals, released by cells within the tumor microenvironment (TME), including cancer cells themselves, as well as infiltrating immune cells, stromal cells, and other components of the extracellular matrix, all can contribute to reshaping the tumor microenvironment (TME) and tumor growth/survival. Most recently, attention has centered on contributions in the TME made by the pro-inflammatory interleukin 17 (IL-17) and the T cells (Th17) and non-T cells which produce this cytokine, as well as the target cells (IL-17 receptor positive, IL-17R+) signaled by IL-17. The IL-17 family itself comprises at least six members, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-17F, all of which are known to be secreted as disulfide-linked homo- or heterodimers. These in turn bind to IL-17R, a type I cell surface receptor, of which at least five variants have been described to date, IL-17RA to IL-17RE. The discussion below focuses on what we know to date about the role of IL-17/IL-17R interactions in the tumor microenvironment in regulation of tumor growth and metastasis and highlights recent ideas concerning the possible utility of this knowledge in the clinic.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74–80

    Article  CAS  PubMed  Google Scholar 

  2. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, Xu H (2010) IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 184:2281–2288

    Article  CAS  PubMed  Google Scholar 

  3. Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bowman RL, Joyce JA (2014) Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. Immunotherapy 6:663–666

    Article  CAS  PubMed  Google Scholar 

  5. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804–811

    Article  CAS  PubMed  Google Scholar 

  6. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998

    Article  CAS  PubMed  Google Scholar 

  7. Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumor immunity: effector response to tumor and role of the microenvironment. Lancet 371:771–783

    Article  CAS  PubMed  Google Scholar 

  8. Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al DR (2016) Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Mol Sci 17:1433–1440

    Article  PubMed Central  CAS  Google Scholar 

  9. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ (1995) Human IL-17: a novel cytokine derived from T cells. J Immunol 155:5483–5486

    CAS  PubMed  Google Scholar 

  10. Majumder S, Amatya N, Revu S, Jawale CV, Wu D, Rittenhouse N, Menk A, Kupul S, Du F, Raphael I, Bhattacharjee A, Siebenlist U, Hand TW, Delgoffe GM, Poholek AC, Gaffen SL, Biswas PS, McGeachy MJ (2019) IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival. Nat Immunol. https://doi.org/10.1038/s41590-019-0367-4. [Epub ahead of print]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Maniati E, Soper R, Hagemann T (2010) Up for mischief? IL-17/Th17 in the tumor microenvironment. Oncogene 29:5653–5662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184:1630–1641

    Article  CAS  PubMed  Google Scholar 

  13. Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, Watanabe G, Tada H, Suzuki A, Ohuchi N et al (2015) Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res 17:124–137

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Gu C, Wu L, Li X (2013) IL-17 family: cytokines, receptors and signaling. Cytokine 64:477–485

    Article  CAS  PubMed  Google Scholar 

  15. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS et al (2008) T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 28:29–39

    Article  CAS  PubMed  Google Scholar 

  16. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR (2007) IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8:967–974

    Article  CAS  PubMed  Google Scholar 

  17. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T et al (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744–748

    Article  CAS  PubMed  Google Scholar 

  18. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F et al (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8:950–957

    Article  CAS  PubMed  Google Scholar 

  19. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D et al (2009) FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 69:3995–4000

    Article  CAS  PubMed  Google Scholar 

  20. Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, Chen L, Wang G, Zou W (2008) Cutting edge: IFNγ enables APC to promote memory Th17 and abate Th1 cell development. J Immunol 181:5842–5846

    Article  CAS  PubMed  Google Scholar 

  21. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787–798

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH et al (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141–1149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Song X, Qian Y (2013) The activation and regulation of IL-17 receptor mediated signaling. Cytokine 62:175–182. https://doi.org/10.1016/j.cyto.2013.03.014. [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  PubMed  Google Scholar 

  24. Xu S, Cao X (2010) Interleukin-17 and its expanding biological functions. Cell Mol Immunol 7:164–174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Chen Z, O’Shea JJ (2008) Regulation of IL-17 production in human lymphocytes. Cytokine 41:71–78

    Article  PubMed  CAS  Google Scholar 

  26. Kirkham BW, Kavanaugh A, Reich K (2014) Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 141:133–142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Toy D, Kugler D, Wolfson M, Vanden BT, Gurgel J, Derry J, Tocker J, Peschon J (2006) Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 177:36–39

    Article  CAS  PubMed  Google Scholar 

  28. Shalom-Barak T, Quach J, Lotz M (1998) Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem 273:27467–27473

    Article  CAS  PubMed  Google Scholar 

  29. Sun F, Qu Z, Xiao Y, Zhou J, Burns TF, Stabile LP, Siegfried JM, Xiao G (2016) NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function. Oncogene 35:2299–2310. https://doi.org/10.1038/onc.2015.299. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  PubMed  Google Scholar 

  30. Ji Y, Zhang W (2010) Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 59:979–987

    Article  PubMed  Google Scholar 

  31. Bronte V (2008) Th17 and cancer: friends or foes? Blood 112:214

    Article  CAS  PubMed  Google Scholar 

  32. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141–1149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM (2009) Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin’s lymphoma. Cancer Res 69:5522–5530

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, Savage P, Stebbing J (2009) The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer 100:1061–1067

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP (2008) Tumor-specific Th17polarized cells eradicate large established melanoma. Blood 112:362–373

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Dougan M, Dranoff G (2008) Inciting inflammation: the RAGE about tumor promotion. J Exp Med 205:267–270

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30:1073–1081

    Article  CAS  PubMed  Google Scholar 

  38. Relation T, Yi T, Guess AJ, La Perle K, Otsuru S, Hasgur S, Dominici M, Breuer C, Horwitz EM (2018) Intratumoral delivery of interferonγ-secreting mesenchymal stromal cells repolarizes tumor-associated macrophages and suppresses neuroblastoma proliferation in vivo. Stem Cells 36(6):915–924. https://doi.org/10.1002/stem.2801. Epub 2018 Feb 27

    Article  CAS  PubMed  Google Scholar 

  39. Charles KA, Kulbe H, Soper R, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T (2009) The tumor promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 119:3011–3023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Yang L, Liu H, Zhang L, Hu J, Chen H, Wang L, Yin X, Li Q, Qi Y (2016) Effect of IL-17 in the development of colon cancer in mice. Oncol Lett 12(6):4929–4936. https://doi.org/10.3892/ol.2016.5329. Epub 2016 Oct 31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Punt S, Langenhoff JM, Putter H, Fleuren GJ, Gorter A, Jordanova ES (2015) The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology 4(2):e984547. eCollection 2015 Feb

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Lee EJ, Park HJ, Lee IJ, Kim WW, Ha SJ, Suh YG, Seong J (2014) Inhibition of IL-17A suppresses enhanced-tumor growth in low dose pre-irradiated tumor beds. PLoS One 9(9):e106423. https://doi.org/10.1371/journal.pone.0106423. eCollection 2014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chen YS, Huang TH, Liu CL, Chen HS, Lee MH, Chen HW, Shen CR (2019) Locally targeting the IL-17/IL-17RA axis reduced tumor growth in a murine B16F10 melanoma model. Hum Gene Ther 30(3):273–285. https://doi.org/10.1089/hum.2018.104. Epub 2018 Oct 3

    Article  CAS  PubMed  Google Scholar 

  44. Darvishi B, Majidzadeh-A K, Ghadirian R, Mosayebzadeh M, Farahmand L (2019) Recruited bone marrow derived cells, local stromal cells and IL-17 at the front line of resistance development to anti-VEGF targeted therapies. Life Sci 217:34–40. https://doi.org/10.1016/j.lfs.2018.11.033. Epub 2018 Nov 22

    Article  CAS  PubMed  Google Scholar 

  45. Darrasse-Jeze G, Bergot A, Cordier C, Ngo-Abdalla S, Klatzmann D, Azogui O (2007) Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol 179:4969–4978

    Article  PubMed  Google Scholar 

  46. Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K, Wang L, Ikarashi Y, Wakasugi H, Nakayama T, Taniguchi M, Kuribayashi K, Old LJ, Shiku H (2005) Accelerated chemically induced tumor development mediated by CD4 +CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A 102:9253–9257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, Chen L, Zou W (2006) Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 177:40–44

    Article  CAS  PubMed  Google Scholar 

  48. Najafi S, Mirshafiey A (2019) The role of T helper 17 and regulatory T cells in tumor microenvironment. Immunopharmacol Immunotoxicol:1–9. https://doi.org/10.1080/08923973.2019.1566925. [Epub ahead of print]

    Article  CAS  PubMed  Google Scholar 

  49. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238

    Article  CAS  PubMed  Google Scholar 

  50. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, Oukka M, Kuchroo VK (2007) IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 448:484–487

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR (2008) TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature 453:236–240

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Downs-Canner S, Berkey S, Delgoffe GM, Edwards RP, Curiel T, Odunsi K, Bartlett DL, Obermajer N (2017) Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells. Nat Commun 8:14649. https://doi.org/10.1038/ncomms14649

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Barilla RM, Diskin B, Caso RC, Lee KB, Mohan N, Buttar C, Adam S, Sekendiz Z, Wang J, Salas RD, Cassini MF, Karlen J, Sundberg B, Akbar H, Levchenko D, Gakhal I, Gutierrez J, Wang W, Hundeyin M, Torres-Hernandez A, Leinwand J, Kurz E, Rossi JAK, Mishra A, Liria M, Sanchez G, Panta J, Loke P, Aykut B, Miller G (2019) Specialized dendritic cells induce tumor-promoting IL-10+IL-17+ FoxP3neg regulatory CD4+ T cells in pancreatic carcinoma. Nat Commun 10(1):1424. https://doi.org/10.1038/s41467-019-09416-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V et al (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59:3698–3704. [PubMed] [Google Scholar]

    CAS  PubMed  Google Scholar 

  55. Punt S, Fleuren GJ, Kritikou E, Lubberts E, Trimbos JB, Jordanova ES, Gorter A (2015) Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology 4:e984539. https://doi.org/10.4161/2162402X.2014.984539. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Haudenschild D, Moseley T, Rose L, Reddi AH (2002) Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem 277:4309–4316. https://doi.org/10.1074/jbc.M109372200. [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  PubMed  Google Scholar 

  57. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ (2003) Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56:171–182. https://doi.org/10.1002/pros.10238. [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  PubMed  Google Scholar 

  58. Zhang Q, Liu S, Parajuli KR, Zhang W, Zhang K, Mo Z, Liu J, Chen Z, Yang S, Wang AR et al (2016) Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene. https://doi.org/10.1038/onc.2016.240. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Li B, Shi XY, Liao DX, Cao BR, Luo CH, Cheng SJ (2015) Advanced colorectal adenoma related gene expression signature may predict prognostic for colorectal cancer patients with adenoma-carcinoma sequence. Int J Clin Exp Med 8:4883–4898. [PMC free article] [PubMed] [Google Scholar]

    CAS  PubMed  PubMed Central  Google Scholar 

  60. He D, Li H, Yusuf N, Elmets CA, Athar M, Katiyar SK, Xu H (2012) IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS One 7:1433. https://doi.org/10.1371/journal.pone.0032126. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  Google Scholar 

  61. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6-STAT3 signaling pathway. J Exp Med 206:1457–1464. https://doi.org/10.1084/jem.20090207. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Doroudchi M, Pishe ZG, Malekzadeh M, Golmoghaddam H, Taghipour M, Ghaderi A (2013) Elevated serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac J Cancer Prev 14:5225–5230. https://doi.org/10.7314/APJCP.2013.14.9.5225. [PubMed] [CrossRef] [Google Scholar]

    Article  PubMed  Google Scholar 

  63. Parajuli P, Anand R, Mandalaparty C, Suryadevara R, Sriranga PU, Michelhaugh SK, Cazacu S, Finniss S, Thakur A, Lum LG et al (2016) Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal. Oncotarget 7:6121–6135. [PMC free article] [PubMed] [Google Scholar]

    PubMed  PubMed Central  Google Scholar 

  64. Wainwright DA, Sengupta S, Han Y, Ulasov IV, Lesniak MS (2010) The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One 5:1433. https://doi.org/10.1371/journal.pone.0015390. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  Google Scholar 

  65. Hu J, Ye H, Zhang D, Liu W, Li M, Mao Y, Lu Y (2013) U87MG glioma cells overexpressing IL-17 accelerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues. Oncol Lett 6:993–999. [PMC free article] [PubMed] [Google Scholar]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Zhu F, McCaw L, Spaner DE, Gorczynski RM (2018) Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro. Leuk Res 66:28–38. https://doi.org/10.1016/j.leukres.2018.01.006. Epub 2018 Jan 17

    Article  CAS  PubMed  Google Scholar 

  67. Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F et al (2014) Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal 7:ra63

    Article  PubMed  CAS  Google Scholar 

  68. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW et al (2007) Mesenchymal stem cells within tumor stroma promote breast cancer metastasis. Nature 449:557–563

    Article  CAS  PubMed  Google Scholar 

  69. Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T et al (2011) Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med 17:579–587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M et al (2010) Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 127:2323–2333

    Article  CAS  PubMed  Google Scholar 

  71. Burgess M, Cheung C, Chambers L, Ravindranath K, Minhas G et al (2012) CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leuk Lymphoma 53:1988–1998

    Article  CAS  PubMed  Google Scholar 

  72. Wilson A, Trumpp A (2006) Bone-marrow hematopoietic-stem-cell niches. Nat Rev Immunol 6:93–106

    Article  CAS  PubMed  Google Scholar 

  73. Lai R, O’Brien S, Maushouri T, Rogers A, Kantarjian H et al (2002) Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 95:1071–1075

    Article  CAS  PubMed  Google Scholar 

  74. Tang D, Niu Q, Jiang N, Li J, Zheng Q et al (2014) Increased frequencies of Th17 in the peripheral blood of patients with chronic lymphocytic leukemia: a one year follow up. Pak J Med Sci 30:1128–1133

    PubMed  PubMed Central  Google Scholar 

  75. Prabhala RH, Fulciniti M, Pelluru D, Rashid N, Nigroiu A et al (2015) Targeting IL17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia 30:379–389

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448–457

    Article  CAS  PubMed  Google Scholar 

  77. Heo T-H, Wahler J, Suh N (2016) Potential therapeutic implications of IL-6/IL-6R/ gp130-targeting agents in breast cancer. Oncotarget 7:15460–15473

    PubMed  PubMed Central  Google Scholar 

  78. Lyon DE, McCain NL, Walter J, Schubert C (2008) Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57:51–58. https://doi.org/10.1097/01.NNR.0000280655.58266.6c. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Article  PubMed  PubMed Central  Google Scholar 

  79. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM et al (2008) IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10:95–106. https://doi.org/10.1186/bcr2195. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  Google Scholar 

  80. Du JW, Xu KY, Fang LY, Qi XL (2012) Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Rep 6:1099–1102. https://doi.org/10.3892/mmr.2012.1036. [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  PubMed  Google Scholar 

  81. Kim G, Khanal P, Lim SC, Yun HJ, Ahn SG, Ki SH, Choi HS (2013) Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity. Carcinogenesis 34:341–350. https://doi.org/10.1093/carcin/bgs342. [PubMed] [CrossRef] [Google Scholar]

    Article  CAS  PubMed  Google Scholar 

  82. Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J et al (2015) IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells. Sci Rep 5:11874–11884. https://doi.org/10.1038/srep11874. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

    Article  PubMed  PubMed Central  Google Scholar 

  83. Gorczynski R, Chen Z, Erin N, Khatri I, Podnos A (2014) Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy. PLoS One 9(11):e113597. https://doi.org/10.1371/journal.pone.0113597

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Erin N, Podnos A, Tanriover G, Duymus O, Cote E, Khatri I, Gorczynski RM (2015) Bidirectional effect of CD200 on breast cancer development and tumor invasion with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene 34(29):3860–3870

    Article  CAS  PubMed  Google Scholar 

  85. Gorczynski RM, Erin N, Zhu F (2016) Serum-derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumor. Cancer Med 5(2):325–336. https://doi.org/10.1002/cam4.575. Epub 2016 Jan 4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Guo D, Chen Y, Wang S, Yu L, Shen Y, Zhong H, Yang Y (2018) Exosomes from heat-stressed tumor cells inhibit tumor growth by converting regulatory T cells to Th17 cells via IL-6. Immunology 154(1):132–143. https://doi.org/10.1111/imm.12874. Epub 2018 Jan 2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Knupfer H, Preiß R (2007) Significance of interleukin-6 (IL-6) in breast cancer. Breast Cancer Res Treat 102:129–135. https://doi.org/10.1007/s10549-006-9328-3

    Article  CAS  PubMed  Google Scholar 

  88. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY (2004) Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10(21):7157–7162

    Article  CAS  PubMed  Google Scholar 

  89. Bar-Eli M (1999) Role of interleukin-8 in tumor growth and tumor invasion of human melanoma. Pathobiology 67:12–18. https://doi.org/10.1159/000028045

    Article  CAS  PubMed  Google Scholar 

  90. XingWu Zhu X-W, Mulcahy LA, Mohammed RAA, Lee AHS, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM, Jackson AM (2008) IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10:R95. https://doi.org/10.1186/bcr2195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau C-S, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, de Visser KE (2015) IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer tumor invasion. Nature 522:345–348. https://doi.org/10.1038/nature14282

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Gorczynski RM, Erin N, Maqbool T, Gorczynski CP, Gorczynski LY (2018) Characterization of an in vitro model system to explore control of tumor invasion of EMT6 and 4THM breast tumors by CD200:CD200R interactions. Breast Cancer 25(5):547–559. https://doi.org/10.1007/s12282-018-0851-y. Epub 2018 Mar 12

    Article  PubMed  Google Scholar 

  93. Gorczynski RM, Zhu F (2017) Checkpoint blockade in solid tumors and B cell malignancies with special consideration of the role of CD200. Cancer Manag Res 9:601–609

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Ma YF, Chen C, Li D, Liu M, Lv ZW, Ji Y (2017) Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Oncotarget 8(5):7614–7624. https://doi.org/10.18632/oncotarget.13819

    Article  PubMed  Google Scholar 

  95. Gorczynski RM, Zhu F, Chen Z, Kos O, Khatri I (2017) A comparison of serum miRNAs influencing metastatic growth of EMT6 vs 4THM tumor cells in wild-type and CD200R1KO mice. Breast Cancer Res Treat 162:255–266

    Article  CAS  PubMed  Google Scholar 

  96. Gu K, Li MM, Shen J, Liu F, Cao JY, Jin S, Yu Y (2015) Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-κB/ZEB1 signal pathway. Am J Cancer Res 5(3):1169–1179. eCollection 2015

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery & Immunology, University of Toronto, Toronto, ON, Canada

    R. M. Gorczynski

Authors
  1. R. M. Gorczynski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. M. Gorczynski .

Editor information

Editors and Affiliations

  1. Department of Radiology, Columbia University Medical Center, New York, NY, USA, Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Alexander Birbrair

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gorczynski, R.M. (2020). IL-17 Signaling in the Tumor Microenvironment. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1240. Springer, Cham. https://doi.org/10.1007/978-3-030-38315-2_4

Download citation

Publish with us

Policies and ethics

Search

Navigation